JNJ-74856665

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-74856665, covering 2025-10-01 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]

See pricing